Pfizer acquires BioRexis in move to boost diabetes, protein drug pipeline

Share this article:
Pfizer said today it has acquired BioRexis Pharmaceutical Corporation, a privately-held biopharmaceutical firm working on several diabetes treatments and a novel technology platform for new protein drug candidates. Financial terms of the deal were not disclosed. The technology being used to develop the experimental treatments relies on protein engineering and may have the potential to improve drug tolerability, reduce dosing frequency and improve patient compliance, Pfizer said.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union